Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical studies with ampligen (mismatched double-stranded RNA).

I Brodsky, D R Strayer, L J Krueger

    Journal of Biological Response Modifiers
    |December 1, 1985
    PubMed
    Summary

    Ampligen, a double-stranded RNA (dsRNA), shows promise in metastatic cancer treatment. This clinical study found Ampligen well-tolerated with evidence of antitumor effects and minimal side effects in patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    High dose cyclophosphamide for severe refractory myasthenia gravis.

    Journal of neurology, neurosurgery, and psychiatry·2004
    Same author

    High-dose cyclophosphamide for severe systemic lupus erythematosus.

    Lupus·2002
    Same author

    High-dose cyclophosphamide without stem-cell rescue for refractory CIDP.

    Neurology·2002
    Same author

    Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia.

    Annals of internal medicine·2001
    Same author

    A current concept of trauma-induced multiorgan failure.

    Annals of emergency medicine·2001
    Same author

    Late onset of severe graft-versus-host disease in a pediatric liver transplant recipient.

    Transplantation·2001

    Area of Science:

    • Immunology
    • Oncology
    • Pharmacology

    Background:

    • Metastatic cancer presents significant treatment challenges.
    • Double-stranded RNA (dsRNA) analogs are being investigated for therapeutic potential.
    • Previous dsRNAs have shown toxicity and antibody formation issues.

    Purpose of the Study:

    • To evaluate the safety and efficacy of Ampligen, a novel dsRNA, in patients with metastatic cancer.
    • To assess the immunologic effects and pharmacokinetic profile of Ampligen.
    • To compare Ampligen's side effect profile with other dsRNAs.

    Main Methods:

    • Clinical study involving patients with hematologic malignancies and solid tumors.
    • Administered Ampligen via intravenous infusion at varying doses (10-80 mg).
    • Monitored for adverse events, hematologic, liver, and renal toxicity, and antibody formation.
    • Assessed biologic/antitumor effects using tumor markers and morphology.
    • Developed a method to monitor Ampligen plasma levels and determined its half-life.

    Main Results:

    • Ampligen was well-tolerated in both pilot and solid tumor studies, with cumulative doses up to 4g.
    • No significant hematologic, liver, or renal toxicity was observed.
    • Mild side effects like fatigue and flu-like symptoms were noted; fever was transient and low-grade.
    • No specific antibodies against Ampligen were detected, unlike other dsRNAs.
    • Evidence of biologic/antitumor effects was observed, including stable disease and tumor regressions in solid tumors.
    • Ampligen activated natural killer (NK) cells and an interferon-associated enzyme.
    • Mean plasma half-life of Ampligen was 23 minutes.

    Conclusions:

    • Ampligen demonstrates a favorable safety profile in metastatic cancer patients.
    • Ampligen exhibits potential antitumor activity and immunomodulatory effects.
    • Ampligen represents a promising therapeutic candidate with reduced immunogenicity compared to other dsRNAs.

    Related Experiment Videos